Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 3
Submit an article Journal homepage
3,989
Views
9
CrossRef citations to date
0
Altmetric
Short Reports

Treatment of patients with chronic pruritus of unknown origin with dupilumab

Jiehyun Jeona Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA;b Center for the Study of Itch and Sensory Disorders, Washington University School of Medicine, St. Louis, MO, USA;c Department of Dermatology, College of Medicine, Korea University, Seoul, KoreaORCID Iconhttps://orcid.org/0000-0003-2456-7573View further author information
ORCID Icon,
Fang Wanga Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA;b Center for the Study of Itch and Sensory Disorders, Washington University School of Medicine, St. Louis, MO, USA;d Department of Dermatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaView further author information
,
Asima Badica Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA;b Center for the Study of Itch and Sensory Disorders, Washington University School of Medicine, St. Louis, MO, USAView further author information
&
Brian S. Kima Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA;b Center for the Study of Itch and Sensory Disorders, Washington University School of Medicine, St. Louis, MO, USA;e Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO, USA;f Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8100-7161View further author information
ORCID Icon
Pages 1754-1757 | Received 02 Jan 2021, Accepted 18 Jan 2021, Published online: 08 Feb 2021

References

  • Kim BS, Berger TG, Yosipovitch G. Chronic pruritus of unknown origin (CPUO): Uniform nomenclature and diagnosis as a pathway to standardized understanding and treatment. J Am Acad Dermatol. 2019;81(5):1223–1224.
  • Millington GWM, Collins A, Lovell CR, et al. British Association of Dermatologists' guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018. Br J Dermatol. 2018;178(1):34–60.
  • Berger TG, Steinhoff M. Pruritus in elderly patients-eruptions of senescence. Semin Cutan Med Surg. 2011;30(2):113–117.
  • Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217–228.e13.
  • Maley A, Swerlick RA. Azathioprine treatment of intractable pruritus: A retrospective review. J Am Acad Dermatol. 2015;73(3):439–443.
  • Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173–182.
  • Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020;382(8):706–716.
  • Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351.
  • Wang F, Morris C, Bodet ND, et al. Treatment of refractory chronic pruritus of unknown origin with tofacitinib in patients with rheumatoid arthritis. JAMA Dermatol. 2019;155(12):1426.
  • Zhai LL, Savage KT, Qiu CC, et al. Chronic pruritus responding to dupilumab—A case series. Medicines. 2019;6(3):72.
  • Clark M, Wang F, Bodet ND, et al. Evaluation of apremilast in chronic pruritus of unknown origin: A proof-of-concept, phase 2a, open-label, single-arm clinical trial. Health Sci Rep. 2020;3(2):e154.
  • A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of serlopitant for the treatment of chronic pruritus of unknown origin. ClinicalTrials.gov identifier: NCT03841331. Updated February 10, 2020. Accessed May 8, 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03841331.
  • A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis. ClinicalTrials.gov identifier: NCT03546816. Updated March 5, 2020. Accessed May 14, 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03546816.
  • Hendricks AJ, Yosipovitch G, Shi VY. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. J Dermatolog Treat. 2021;32(1):19–28.
  • Yang EJ, Murase JE. Recalcitrant anal and genital pruritus treated with dupilumab. Int J Womens Dermatol. 2018;4(4):223–226.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.